147 related articles for article (PubMed ID: 3192459)
1. Use of narcotic antagonists to modify stereotypic self-licking, self-chewing, and scratching behavior in dogs.
Dodman NH; Shuster L; White SD; Court MH; Parker D; Dixon R
J Am Vet Med Assoc; 1988 Oct; 193(7):815-9. PubMed ID: 3192459
[TBL] [Abstract][Full Text] [Related]
2. Naltrexone-induced pruritus in a dog with tail-chasing behavior.
Schwartz S
J Am Vet Med Assoc; 1993 Jan; 202(2):278-80. PubMed ID: 8428834
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic dermatitis.
Herzog JL; Solomon JA; Draelos Z; Fleischer A; Stough D; Wolf DI; Abramovits W; Werschler W; Green E; Duffy M; Rothaul A; Tansley R
J Drugs Dermatol; 2011 Aug; 10(8):853-60. PubMed ID: 21818506
[TBL] [Abstract][Full Text] [Related]
4. Naltrexone for treatment of acral lick dermatitis in dogs.
White SD
J Am Vet Med Assoc; 1990 Apr; 196(7):1073-6. PubMed ID: 2329076
[TBL] [Abstract][Full Text] [Related]
5. Investigation into the use of narcotic antagonists in the treatment of a stereotypic behavior pattern (crib-biting) in the horse.
Dodman NH; Shuster L; Court MH; Dixon R
Am J Vet Res; 1987 Feb; 48(2):311-9. PubMed ID: 3826875
[TBL] [Abstract][Full Text] [Related]
6. Use of a narcotic antagonist (nalmefene) to suppress self-mutilative behavior in a stallion.
Dodman NH; Shuster L; Court MH; Patel J
J Am Vet Med Assoc; 1988 Jun; 192(11):1585-6. PubMed ID: 3410777
[TBL] [Abstract][Full Text] [Related]
7. The use of dextromethorphan to treat repetitive self-directed scratching, biting, or chewing in dogs with allergic dermatitis.
Dodman NH; Shuster L; Nesbitt G; Weissman A; Lo WY; Chang WW; Cottam N
J Vet Pharmacol Ther; 2004 Apr; 27(2):99-104. PubMed ID: 15096107
[TBL] [Abstract][Full Text] [Related]
8. Effects of naltrexone on spontaneous itch-associated responses in NC mice with chronic dermatitis.
Maekawa T; Yamaguchi-Miyamoto T; Nojima H; Kuraishi Y
Jpn J Pharmacol; 2002 Oct; 90(2):193-6. PubMed ID: 12419891
[TBL] [Abstract][Full Text] [Related]
9. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.
Bergasa NV; Schmitt JM; Talbot TL; Alling DW; Swain MG; Turner ML; Jenkins JB; Jones EA
Hepatology; 1998 Mar; 27(3):679-84. PubMed ID: 9500694
[TBL] [Abstract][Full Text] [Related]
10. Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation.
Wilhelm JA; Veng-Pedersen P; Zakszewski TB; Osifchin E; Waters SJ
Int J Clin Pharmacol Ther; 1995 Oct; 33(10):540-5. PubMed ID: 8574503
[TBL] [Abstract][Full Text] [Related]
11. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
June HL; Grey C; Warren-Reese C; Durr LF; Ricks-Cord A; Johnson A; McCane S; Williams LS; Mason D; Cummings R; Lawrence A
Alcohol Clin Exp Res; 1998 Dec; 22(9):2174-85. PubMed ID: 9884166
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.
Malekzad F; Arbabi M; Mohtasham N; Toosi P; Jaberian M; Mohajer M; Mohammadi MR; Roodsari MR; Nasiri S
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):948-50. PubMed ID: 19453814
[TBL] [Abstract][Full Text] [Related]
13. Treatment of pruritus with topically applied opiate receptor antagonist.
Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
[TBL] [Abstract][Full Text] [Related]
14. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys.
France CP; Gerak LR
J Pharmacol Exp Ther; 1994 Sep; 270(3):992-9. PubMed ID: 7932212
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone as a treatment for repetitive self-injurious behaviour:an open-label trial.
Roth AS; Ostroff RB; Hoffman RE
J Clin Psychiatry; 1996 Jun; 57(6):233-7. PubMed ID: 8666558
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates.
Simpkins JW; Smulkowski M; Dixon R; Tuttle R
J Pharmacol Exp Ther; 1988 Jan; 244(1):195-205. PubMed ID: 3335997
[TBL] [Abstract][Full Text] [Related]
17. Characterizations of sphingosylphosphorylcholine-induced scratching responses in ICR mice using naltrexon, capsaicin, ketotifen and Y-27632.
Kim HJ; Kim H; Han ES; Park SM; Koh JY; Kim KM; Noh MS; Kim JJ; Lee CH
Eur J Pharmacol; 2008 Mar; 583(1):92-6. PubMed ID: 18289521
[TBL] [Abstract][Full Text] [Related]
18. Limitations on the antagonistic actions of opioid antagonists.
Young AM; Woods JH
Fed Proc; 1982 May; 41(7):2333-8. PubMed ID: 7042396
[TBL] [Abstract][Full Text] [Related]
19. Reinstatement of cocaine-seeking behavior in rats is attenuated following repeated treatment with the opioid receptor antagonist naltrexone.
Gerrits MA; Kuzmin AV; van Ree JM
Eur Neuropsychopharmacol; 2005 May; 15(3):297-303. PubMed ID: 15820419
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of passive cutaneous anaphylaxis-associated scratching behavior by mu-opioid receptor antagonists in ICR mice.
Inagaki N; Nakamura N; Nagao M; Kawasaki H; Nagai H
Int Arch Allergy Immunol; 2000 Dec; 123(4):365-8. PubMed ID: 11146395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
